Agenus is a Lexington, Massachusetts biotechnology company developing immunotherapies for cancer and autoimmune diseases. AGEN reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 5 | Chardan Capital | Maintained | Buy | |
| Sep 28 | Rodman & Renshaw | Initiated | Buy | |
| Sep 18 | Chardan Capital | Initiated | Buy | |
| Aug 11 | HC Wainwright & Co. | Target lowered | Buy | |
| Jul 30 | B. Riley Securities | Maintained | Buy |
Seasonality
How AGEN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in AGEN in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AGEN is in one of them and how their past AGEN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AGEN in an article yet. Here's the latest on the wider market.
About Agenus
Agenus is a biotechnology company based in Lexington, Massachusetts. It is developing immunotherapy product candidates aimed at cancer and autoimmune diseases. Its target customers are physicians and patients, and sales depend heavily on coverage and reimbursement from insurers and government healthcare programs. Its product candidates have not yet received marketing approval, and it competes with established treatments such as chemotherapy and radiation therapy.
- Headquarters
- Lexington, MA
- Founded
- 1994
- Website
- agenusbio.com ↗